NLRP3炎症小体在糖尿病肾病发病机制中的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.24.002

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (24): 3532-3537.DOI: 10.3760/cma.j.issn.1007-1245.2023.24.002

NLRP3炎症小体在糖尿病肾病发病机制中的研究进展

李梦洁梁栋邢文华林千愉张慧张晓敏

滨州医学院附属医院肾内科，滨州　256603

收稿日期:2023-05-29 出版日期:2023-12-15 发布日期:2024-01-04
通讯作者: 张晓敏，Email：zhangxiaomin7926@126.com
基金资助:
山东省医药卫生科技发展计划项目（2017WS689）；滨州医学院科技计划项目（BY2021KJ07）

Research progress of NLRP3 inflammasome in pathogenesis of diabetic nephropathy

Li Mengjie, Liang Dong, Xing Wenhua, Lin Qianyu, Zhang Hui, Zhang Xiaomin

Department of Nephrology, Binzhou Medical University Hospital, Binzhou 256603, China

Received:2023-05-29 Online:2023-12-15 Published:2024-01-04
Contact: Zhang Xiaomin, Email: zhangxiaomin7926@126.com
Supported by:
Project of Plan of Medical and Health Science and Technology Development in Shandong Province (2017WS689); Project of Science and Technology Plan of Binzhou Medical University (BY2021KJ07)

摘要/Abstract

摘要：

糖尿病肾病（DN）是糖尿病常见的并发症，与糖尿病患者的病死率增加密切相关。炎症反应是DN发生发展的重要环节。核苷酸结合寡聚化结构域样受体蛋白3（NLRP3）炎症小体作为近些年研究最深入的炎症小体，其异常的活化也被证明与DN的进展呈正相关。本文主要对NLRP3炎症小体在DN中的发病机制及研究进展进行综述。

关键词:

糖尿病肾病, 核苷酸结合寡聚化结构域样受体蛋白3, 足细胞, 进展

Abstract:

Diabetic nephropathy (DN) is one of the most common and serious complications of diabetes and is associated with increased mortality in patients with diabetes. Inflammation is an important part of the development of DN. Nucleotide-binding oligomerizing domain-like receptor protein 3 (NLRP3) inflammasome is the most deeply studied inflammasome in recent years, and its abnormal activation has also been shown to be positively correlated with the progression of DN. This article mainly reviews the pathogenesis and research progress of NLRP3 inflammasome in DN.

Key words:

Diabetic nephropathy, Nucleotide-binding oligomerizing domain-like receptor protein 3, Podocyte, Progress

李梦洁梁栋邢文华林千愉张慧张晓敏.

NLRP3炎症小体在糖尿病肾病发病机制中的研究进展 [J]. 国际医药卫生导报, 2023, 29(24): 3532-3537.

Li Mengjie, Liang Dong, Xing Wenhua, Lin Qianyu, Zhang Hui, Zhang Xiaomin.

Research progress of NLRP3 inflammasome in pathogenesis of diabetic nephropathy [J]. International Medicine and Health Guidance News, 2023, 29(24): 3532-3537.

参考文献

[1] Weir MA, Herzog CA. Beta blockers in patients with end-stage renal disease-evidence-based recommendations[J]. Semin Dial, 2018 ,31(3):219-225. DOI: 10.1111/sdi.12691.
[2] Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, et al. Inflammatory targets in diabetic nephropathy[J]. J Clin Med, 2020,9(2):458. DOI: 10.3390/jcm9020458.
[3] Zhang H, Wang Z. Effect and regulation of the NLRP3 inflammasome during renal fibrosis[J]. Front Cell Dev Biol, 2020 ,7:379. DOI: 10.3389/fcell.2019.00379.
[4] Yang J, Liu Z, Xiao TS. Post-translational regulation of inflammasomes[J]. Cell Mol Immunol, 2017,14(1):65-79. DOI: 10.1038/cmi.2016.29.
[5] Liu P, Zhang Z, Li Y. Relevance of the pyroptosis-related inflammasome pathway in the pathogenesis of diabetic kidney disease[J]. Front Immunol, 2021 ,12:603416. DOI: 10.3389/fimmu.2021.603416.
[6] Yu ZW, Zhang J, Li X, et al. A new research hot spot: the role of NLRP3 inflammasome activation, a key step in pyroptosis, in diabetes and diabetic complications[J]. Life Sci, 2020 ,240:117138. DOI: 10.1016/j.lfs.2019.117138.
[7] Yang Y, Li J, Han TL, et al. Endoplasmic reticulum stress may activate NLRP3 inflammasomes via TXNIP in preeclampsia[J]. Cell Tissue Res, 2020 ,379(3):589-599. DOI: 10.1007/s00441-019-03104-9.
[8] Wang S, Zhao X, Yang S, et al. Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway[J]. Chem Biol Interact, 2017 ,278:48-53. DOI: 10.1016/j.cbi.2017.10.012.
[9] An X, Zhang Y, Cao Y, et al. Punicalagin protects diabetic nephropathy by inhibiting pyroptosis based on TXNIP/NLRP3 pathway[J]. Nutrients, 2020 ,12(5):1516. DOI: 10.3390/nu12051516.
[10] Zhao W, Zhou L, Novák P, et al. Metabolic dysfunction in the regulation of the NLRP3 inflammasome activation: a potential target for diabetic nephropathy[J]. J Diabetes Res, 2022 ,2022:2193768. DOI: 10.1155/2022/2193768.
[11] Li N, Zhao T, Cao Y, et al. Tangshen formula attenuates diabetic kidney injury by imparting anti-pyroptotic effects via the TXNIP-NLRP3-GSDMD axis[J]. Front Pharmacol, 2021 ,11:623489. DOI: 10.3389/fphar.2020. 623489.
[12] 宋瑞婧,张欣欣,高飞,等. 加味升降散对糖尿病肾病大鼠TXNIP/NLRP3通路及足细胞焦亡的影响[J]. 中药药理与临床,2022,38(4):2-9.
[13] 沈梦婷,白丹妮,王庆伟,等. 肉桂及其活性成分抗炎作用机制的研究进展[J]. 中草药,2022,53(10):3218-3225. DOI:10.7501/j.issn.0253-2670.2022.10.032.
[14] Samra YA, Said HS, Elsherbiny NM, et al. Cepharanthine and piperine ameliorate diabetic nephropathy in rats: role of NF-κB and NLRP3 inflammasome[J]. Life Sci, 2016,157:187-199. DOI: 10.1016/j.lfs.2016.06.002.
[15] Yaribeygi H, Simental-Mendía LE, Butler AE, et al. Protective effects of plant-derived natural products on renal complications[J]. J Cell Physiol, 2019 ,234(8):12161-12172. DOI: 10.1002/jcp.27950.
[16] Shen J, Dai Z, Li Y, et al. TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy[J]. Diabetol Metab Syndr, 2022 ,14(1):26. DOI: 10.1186/s13098-021- 00780-y.
[17] Cornut M, Bourdonnay E, Henry T. Transcriptional regulation of inflammasomes[J]. Int J Mol Sci, 2020,21(21):8087. DOI: 10.3390/ijms21218087.
[18] Wang Y, Yu B, Wang L, et al. Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus[J]. PLoS One, 2017 ,12(7):e0181248. DOI: 10.1371/journal.pone.0181248.
[19] 王文文,韩文贝,万毅刚,等. 糖尿病肾病NLRP3炎症小体活化的分子调控机制及中药的干预作用[J]. 中国中药杂志,2020,45(1):7-13. DOI:10.19540/j.cnki.cjcmm. 20190618.402.
[20] Zhu X, Shi J, Li H. Liquiritigenin attenuates high glucose-induced mesangial matrix accumulation, oxidative stress, and inflammation by suppression of the NF-κB and NLRP3 inflammasome pathways[J]. Biomed Pharmacother, 2018 ,106:976-982. DOI: 10.1016/j.biopha.2018.07.045.
[21] Tseng CY, Wang JS, Chao MW. Causation by diesel exhaust particles of endothelial dysfunctions in cytotoxicity, pro-inflammation, permeability, and apoptosis induced by ROS generation[J]. Cardiovasc Toxicol, 2017 ,17(4):384-392. DOI: 10.1007/s12012-016-9364-0.
[22] Wang K, Lv Q, Miao YM, et al. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway[J]. Biochem Pharmacol, 2018 ,155:494-509. DOI: 10.1016/j.bcp.2018.07.039.
[23] Shahzad K, Bock F, Al-Dabet MM, et al. Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy[J].Sci Rep,2016,6:34228.DOI: 10.1038/srep34228.
[24] Sun X, Wang P, Yao LP, et al. Paeonol alleviated acute alcohol-induced liver injury via SIRT1/Nrf2/NF-κB signaling pathway[J]. Environ Toxicol Pharmacol,2018,60:110-117.DOI: 10.1016/j.etap.2018.04.016.
[25] 张彬,张雪涟,张晨阳,等. 冠心丹参方调控Nrf2信号通路治疗糖尿病肾病的作用研究[J]. 中国中药杂志,2020,45(11):2595-2600. DOI:10.19540/j.cnki.cjcmm.20200418.401.
[26] 董奥,谭小月,孔琪,等. 五味子醇提液对糖尿病肾病小鼠氧化应激的保护作用及机制研究[J]. 中草药,2019,50(24):6038-6044. DOI:10.7501/j.issn.0253-2670.2019.24.018.
[27] 罗影,左中夫,程雪,等. 葛花总黄酮通过Nrf2/HO-1信号通路对1型糖尿病大鼠肾脏的保护作用[J]. 中成药,2021,43(11):3178-3182. DOI:10.3969/j.issn.1001-1528. 2021.11.047.
[28] Zhu Y, Zhu C, Yang H, et al. Protective effect of ginsenoside Rg5 against kidney injury via inhibition of NLRP3 inflammasome activation and the MAPK signaling pathway in high-fat diet/streptozotocin-induced diabetic mice[J]. Pharmacol Res,2020,155:104746.DOI: 10.1016/j.phrs.2020.104746.
[29] Lin J, Cheng A, Cheng K, et al. New insights into the mechanisms of pyroptosis and implications for diabetic kidney disease[J]. Int J Mol Sci, 2020,21(19):7057.DOI: 10.3390/ijms21197057.
[30] He B, Li QY, Wu YY, et al. Cyclosporin a protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways[J]. Reprod Biol Endocrinol,2020,18(1):100.DOI: 10.1186/s12958-020-00658-0.
[31] Parveen A, Jin M, Kim SY. Bioactive phytochemicals that regulate the cellular processes involved in diabetic nephropathy[J]. Phytomedicine,2018,39:146-159.DOI: 10.1016/j.phymed.2017.12.018.
[32] Shi L, Hao Z, Zhang S,et al. Baicalein and baicalin alleviate acetaminophen-induced liver injury by activating Nrf2 antioxidative pathway: the involvement of ERK1/2 and PKC[J]. Biochem Pharmacol,2018,150:9-23.DOI: 10.1016/j.bcp.2018.01.026.
[33] Ghonime MG, Shamaa OR, Das S, et al. Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function[J]. J Immunol,2014,192(8):3881-3888.DOI: 10.4049/jimmunol.1301974.
[34] Zahid A, Li B, Kombe AJK,et al. Pharmacological inhibitors of the NLRP3 inflammasome[J]. Front Immunol,2019 ,10:2538.DOI: 10.3389/fimmu.2019.02538.
[35] Ge C , Xu M , Qin Y ,et al. Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP3-regulated inflammation[J]. Food Funct,2019,10(5):2970-2985.DOI: 10.1039/c8fo01653d.
[36] 杨鹏,刘铜华,吴丽丽,等. 中药基于p38 MAPK信号通路干预糖尿病肾病的研究进展[J]. 中国实验方剂学杂志,2023,29(11):212-223. DOI:10.13422/j.cnki.syfjx.20230139.

NLRP3炎症小体在糖尿病肾病发病机制中的研究进展

Research progress of NLRP3 inflammasome in pathogenesis of diabetic nephropathy

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	陈文清管保章. 糖尿病肾病合并妊娠研究进展 [J]. 国际医药卫生导报, 2024, 30(1): 15-20.
[2]	商冠华田春梅. Nrf2信号通路作为虾青素治疗新靶点的研究进展 [J]. 国际医药卫生导报, 2024, 30(1): 20-24.
[3]	王玉芹刘圣勋彭新国. 血脂异常的分类及治疗进展 [J]. 国际医药卫生导报, 2024, 30(1): 24-27.
[4]	刘玉姣王超刘菲. 中西医结合治疗产后盆底肌筋膜疼痛的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1204-1207.
[5]	王泽川黄月琴. 急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.
[6]	徐仕杰罗泽斌陈晓东. CT肺动脉成像在肺栓塞诊治中的应用进展 [J]. 国际医药卫生导报, 2023, 29(8): 1053-1056.
[7]	张衡潘广涛殷鸣张平尹霞. 自体脂肪移植在整形外科中的研究进展 [J]. 国际医药卫生导报, 2023, 29(7): 889-892.
[8]	吴雪梅张玉杰解胜华. 银屑病与心血管共病关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 453-456.
[9]	罗思何均初梁茵茹李振洲. 产后腹直肌分离的高频超声特征及其与分娩方式相关性的研究进展 [J]. 国际医药卫生导报, 2023, 29(24): 3529-3532.
[10]	戚燕芝吴艳萍. 服用二甲双胍的2型糖尿病患者进行碘造影剂检查的研究进展 [J]. 国际医药卫生导报, 2023, 29(24): 3537-3541.
[11]	房祥芳黄钰洁李岩峰王忠永. 特应性皮炎的靶向治疗新进展 [J]. 国际医药卫生导报, 2023, 29(24): 3546-3550.
[12]	耿泽月张兴凯杜刚强周楠赵冬阳王志刚. 髓内钉治疗股骨中下段骨折的并发症分析 [J]. 国际医药卫生导报, 2023, 29(23): 3321-3324.
[13]	张辰喜王鹏飞潘欣刘紫仪张勇. 艾司氯胺酮在临床麻醉中的应用进展 [J]. 国际医药卫生导报, 2023, 29(23): 3325-3329.
[14]	肖曦　石斗飞. 维生素C在呼吸道感染中应用的研究进展 [J]. 国际医药卫生导报, 2023, 29(23): 3330-3335.
[15]	司航王娜娜刘素素张骞. PP1A在肿瘤发生发展过程中的作用及研究进展 [J]. 国际医药卫生导报, 2023, 29(23): 3336-3340.